Hassan Abdalshafy

Hassan Abdalshafy


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
ATAya Turki
Aya Turki
KAKirellos Said Abbas
Kirellos Said Abbas
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
MEMostafa Elfert
Mostafa Elfert
MEMahmoud Elmarabea
Mahmoud Elmarabea
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy

4 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
AMAbdelrahman Mahmoud
Abdelrahman Mahmoud
MAMohamed Abuelazm
Mohamed Abuelazm
Ali Ashraf Salah AhmedAli Ashraf Salah Ahmed
Ali Ashraf Salah Ahmed
HAHassan Abdalshafy
Hassan Abdalshafy
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
James Robert BrasicJames Robert Brasic
James Robert Brasic
Helicobacter pylori (H. pylori) is the most prevalent etiology of gastritis worldwide. H. pylori management depends mainly on antibiotics, especially the triple therapy formed of clarithromycin, amoxicillin, and proton pump inhibitors. Lately, many antibiotic-resistant strains have emerged, leading to a decrease in the eradication rates of H. pylori. Polaprezinc (PZN), a mucosal protective zinc-L-carnosine complex, may be a non-antibiotic agent to treat H. pylori without the risk of resistance. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of a PZN-based regimen for the eradication of H. pylori. This study used a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, SCOPUS, EMBASE, PubMed, and Google Scholar until 25 July 2022. We used the odds ratio (OR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022349231. We included 3 trials with a total of 396 participants who were randomized to either PZN plus triple therapy (n = 199) or triple therapy alone (control) (n = 197). Pooled OR found a statistical difference favoring the PZN arm in the intention to treat and per protocol H. pylori eradication rates (OR: 2.01 with 95% CI [1.27, 3.21], p = 0.003) and (OR: 2.65 with 95% CI [1.55, 4.54], p = 0.0004), respectively. We found no statistical difference between the two groups regarding the total adverse events (OR: 1.06 with 95% CI [0.55, 2.06], p = 0.85). PZN, when added to the triple therapy, yielded a better effect concerning the eradication rates of H. pylori with no difference in adverse event rates, and thus can be considered a valuable adjuvant for the management of H. pylori. However, the evidence is still scarce, and larger trials are needed to confirm or refute our findings.